Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846365 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
A Phase 3 study of Essential Hypertension, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,085
- Enrollment target
- 20
- Study locations
NCT00846365: Completed Phase 3 study of Essential Hypertension, sponsored by Takeda.
NCT00846365 is a Phase 3 study of Essential Hypertension that has completed, run by Takeda. The registered enrollment target is 1,085 participants, above the 668-participant average among 8 other Essential Hypertension trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00846365, a Phase 3 study of Essential Hypertension, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,085 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.
Primary Outcome
The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
Conditions Studied
Interventions
- DRUG Azilsartan medoxomil and chlorthalidone
- DRUG Olmesartan medoxomil-hydrochlorothiazide
Study Locations (20)
Florida
- - Clearwater
- - Jacksonville
- - Jupiter
- - Miami
- - Ocala
- - Pembroke Pines
- - Plant City
Alabama
- - Birmingham
- - Haleyville
- - Hueytown
- - Jasper
- - Tallassee
California
- - Long Beach
- - National City
- - Roseville
- - San Francisco
- - San Jose
Arizona
- - Green Valley
- - Phoenix
Delaware
- - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,085 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00846365 record still lists
NCT00846365 is an interventional study that assigns participants to a tested intervention. Its 1,085 participants enrollment target places it among the larger protocols in the corpus, above the 668-participant average among 8 other Essential Hypertension trials with a reported enrollment target (62% higher).
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Azilsartan medoxomil and chlorthalidone is the first listed.
NCT00846365 names 20 study sites across 5 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00846365 about?
NCT00846365 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension". The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.
What is the current status of trial NCT00846365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,085 participants. The study started on 2009-03. Estimated completion is 2010-06.
What conditions does trial NCT00846365 study?
This clinical trial studies the following conditions: Essential Hypertension.
What interventions are being tested in trial NCT00846365?
The interventions under investigation include: Azilsartan medoxomil and chlorthalidone (DRUG), Olmesartan medoxomil-hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00846365?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00846365 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00846365's enrollment target sits among peer trials
1,085 3rd of 8 higher than 6 of 8 other Essential Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Essential Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
COMPLETED · Phase 3
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
ACTIVE NOT RECRUITING
-
Uric Acid in Essential Hypertension in Children
COMPLETED · Phase 2
-
Hypertension: Prediction of Biofeedback Success
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia